Alanine Aminotransferase and Gamma‐Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis. Issue 3 (30th November 2020)

• Record Type: Journal Article
• Authors: Newton, Kimberly P.; Lavine, Joel E.; Wilson, Laura; Behling, Cynthia; Vos, Miriam B.; Molleston, Jean P.; Rosenthal, Philip; Miloh, Tamir; Fishbein, Mark H.; Jain, Ajay K.; Murray, Karen F.; Schwimmer, Jeffrey B.
• Is Part Of: Hepatology. Volume 73:Issue 3(2021)
• Page Start: 937
• Page End: 951
• Publication Date: 2020-11-30
• Subjects: Heart -- Diseases -- Nursing -- Periodicals; Lungs -- Diseases -- Nursing -- Periodicals; Intensive care nursing -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1002/hep.31317
• Languages: English
• ISSNs: 0270-9139

Abstract

Abstract : Background and Aims: Predictive, noninvasive tools are needed to monitor key features of nonalcoholic fatty liver disease (NAFLD) in children that relate to improvement in liver histology. The purpose of this study was to evaluate the relationship between liver chemistries and liver histology using data from the CyNCh (Cysteamine Bitartrate Delayed‐Release for the Treatment of NAFLD in Children) clinical trial. Approach and Results: This study included 146 children. Improvement in liver histology, defined as decrease in nonalcoholic fatty liver disease (NAFLD) Activity Score ≥2 points without worsening of fibrosis, occurred in 43 participants (30%). There were 46 participants with borderline zone 1 nonalcoholic steatohepatitis (NASH) at baseline, with resolution in 28% (12 of 46). Multivariate models were constructed using baseline and change in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma‐glutamyl transferase (GGT) at 52 weeks, for improvement in (1) liver histology primary outcome, (2) borderline zone 1 NASH, and (3) fibrosis. For improvement in histology, the model ( P < 0.0001) retained baseline and change in GGT (area under the receiver operating characteristic [AUROC], 0.79; 95% confidence interval [CI], 0.71‐0.87). For borderline zone 1 NASH, the model ( P = 0.0004) retained baseline and change in ALT (AUROC, 0.80; 95% CI, 0.67‐0.93). For fibrosis, the model ( P < 0.001) retained baseline and change in ALT (AUROC, 0.80; 95% CI, 0.67‐0.93). Additional clinical parameters were added to the models using Akaike's information criterion selection, and significantly boosted performance: improvement in histology with AUROC of 0.89 (95% CI, 0.82‐0.95), borderline zone 1 NASH with AUROC of 0.91 (95% CI, 0.83‐0.99), and fibrosis with AUROC of 0.89 (95% CI, 0.82‐0.94). Models were validated using data from the TONIC (Treatment of Nonalcoholic Fatty Liver Disease in Children) trial. Conclusions: In children with NAFLD, dynamic changes in serum ALT and GGT are associated with change in liver histology and appear to be powerful indicators of histological response.